reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

2seventy bio, Inc.

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

$198Mstalepublic float
2025-03-17most recent failure
2025-05-13delisted or deregistered

Score over time

012202220232024202520262025-04-01 · score 12025-03-17 filed late (10-K) · acquisition or merger2025-07-01 · score 12025-03-17 filed late (10-K) · acquisition or merger2025-10-01 · score 12025-03-17 filed late (10-K) · acquisition or merger2026-01-01 · score 12025-03-17 filed late (10-K) · acquisition or merger

Hover or tap a dot to see the filings behind that score.

Why they said they were late

The Annual Report on Form 10-K for the period ended December 31, 2024 (the “Annual Report”) of 2seventy bio, Inc. (the “Company”) could not be filed within the prescribed time period due to the time and resources required for the Company to (i) negotiate the proposed acquisition of the Company pursuant to the Agreement and Plan of Merger by and among Bristol-Myers Squibb Company (“BMS”), Daybreak Merger Sub Inc. and the Company, dated as of March 10, 2025 (the “Proposed Acquisition”), and (ii) complete the Company’s 2024 financial statement close and related financial reporting process. The Company intends to file the Annual Report within the fifteen-day extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934

NT 10-K, filed 2025-03-17 · acquisition or merger

What it filed

2025-03-17filed late (10-K)acquisition or merger SEC →

The Annual Report on Form 10-K for the period ended December 31, 2024 (the “Annual Report”) of 2seventy bio, Inc. (the “Company”) could not be filed within the prescribed time period due to the time and resources required for the Company to (i) negotiate the proposed acquisition of the Company pursuant to the Agreement and Plan of Merger by and among Bristol-Myers Squibb Company (“BMS”), Daybreak Merger Sub Inc. and the Company, dated as of March 10, 2025 (the “Proposed Acquisition”), and (ii) complete the Company’s 2024 financial statement close and related financial reporting process. The Company intends to file the Annual Report within the fifteen-day extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com